|
Gene: ZNF770 |
Gene summary for ZNF770 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ZNF770 | Gene ID | 54989 |
Gene name | zinc finger protein 770 | |
Gene Alias | PRO1914 | |
Cytomap | 15q14 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q6IQ21 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54989 | ZNF770 | LZE2T | Human | Esophagus | ESCC | 3.45e-06 | 5.33e-01 | 0.082 |
54989 | ZNF770 | LZE4T | Human | Esophagus | ESCC | 1.35e-14 | 2.78e-01 | 0.0811 |
54989 | ZNF770 | LZE8T | Human | Esophagus | ESCC | 1.56e-04 | -2.94e-02 | 0.067 |
54989 | ZNF770 | LZE20T | Human | Esophagus | ESCC | 4.78e-02 | -4.30e-02 | 0.0662 |
54989 | ZNF770 | LZE24T | Human | Esophagus | ESCC | 7.30e-13 | 1.29e-01 | 0.0596 |
54989 | ZNF770 | LZE21T | Human | Esophagus | ESCC | 1.60e-02 | 1.15e-01 | 0.0655 |
54989 | ZNF770 | LZE6T | Human | Esophagus | ESCC | 1.18e-03 | -6.62e-03 | 0.0845 |
54989 | ZNF770 | P1T-E | Human | Esophagus | ESCC | 4.80e-03 | 2.20e-01 | 0.0875 |
54989 | ZNF770 | P2T-E | Human | Esophagus | ESCC | 6.86e-25 | 2.34e-01 | 0.1177 |
54989 | ZNF770 | P4T-E | Human | Esophagus | ESCC | 1.47e-17 | 6.23e-01 | 0.1323 |
54989 | ZNF770 | P5T-E | Human | Esophagus | ESCC | 6.29e-16 | 3.45e-01 | 0.1327 |
54989 | ZNF770 | P8T-E | Human | Esophagus | ESCC | 7.45e-21 | 3.25e-01 | 0.0889 |
54989 | ZNF770 | P9T-E | Human | Esophagus | ESCC | 2.31e-13 | 1.52e-01 | 0.1131 |
54989 | ZNF770 | P10T-E | Human | Esophagus | ESCC | 3.28e-29 | 6.04e-01 | 0.116 |
54989 | ZNF770 | P11T-E | Human | Esophagus | ESCC | 1.77e-07 | 2.40e-01 | 0.1426 |
54989 | ZNF770 | P12T-E | Human | Esophagus | ESCC | 3.32e-23 | 3.89e-01 | 0.1122 |
54989 | ZNF770 | P15T-E | Human | Esophagus | ESCC | 2.91e-23 | 3.95e-01 | 0.1149 |
54989 | ZNF770 | P16T-E | Human | Esophagus | ESCC | 2.40e-28 | 5.21e-01 | 0.1153 |
54989 | ZNF770 | P19T-E | Human | Esophagus | ESCC | 6.06e-06 | 1.52e-01 | 0.1662 |
54989 | ZNF770 | P20T-E | Human | Esophagus | ESCC | 1.44e-14 | 2.28e-01 | 0.1124 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF770 | SNV | Missense_Mutation | c.208N>G | p.Leu70Val | p.L70V | Q6IQ21 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-HC-A4ZV-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Unknown | Unknown | SD | |
ZNF770 | SNV | Missense_Mutation | novel | c.1646N>T | p.Ser549Leu | p.S549L | Q6IQ21 | protein_coding | tolerated(0.08) | benign(0) | TCGA-V1-A8WS-01 | Prostate | prostate adenocarcinoma | Male | <65 | 6 | Unknown | Unknown | SD |
ZNF770 | SNV | Missense_Mutation | novel | c.170N>T | p.Cys57Phe | p.C57F | Q6IQ21 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-YJ-A8SW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | SD |
ZNF770 | SNV | Missense_Mutation | c.2069N>C | p.Val690Ala | p.V690A | Q6IQ21 | protein_coding | tolerated_low_confidence(0.08) | benign(0.039) | TCGA-BR-7707-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZNF770 | SNV | Missense_Mutation | c.479N>T | p.His160Leu | p.H160L | Q6IQ21 | protein_coding | deleterious(0) | possibly_damaging(0.791) | TCGA-CD-8535-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | docetaxel | CR | |
ZNF770 | SNV | Missense_Mutation | c.158N>G | p.Lys53Arg | p.K53R | Q6IQ21 | protein_coding | tolerated(0.13) | probably_damaging(0.998) | TCGA-CD-A48A-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | capecitabine | CR | |
ZNF770 | SNV | Missense_Mutation | c.184A>G | p.Lys62Glu | p.K62E | Q6IQ21 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CG-5721-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
ZNF770 | SNV | Missense_Mutation | c.2066N>T | p.Ser689Leu | p.S689L | Q6IQ21 | protein_coding | deleterious_low_confidence(0.02) | benign(0.003) | TCGA-D7-A4YV-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZNF770 | insertion | Frame_Shift_Ins | novel | c.1253dupA | p.Asn418LysfsTer15 | p.N418Kfs*15 | Q6IQ21 | protein_coding | TCGA-CD-A4MG-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
ZNF770 | insertion | Nonsense_Mutation | novel | c.1309_1310insGTTAACATTATTACCTGAATGATT | p.Lys437delinsSerTerHisTyrTyrLeuAsnAspTer | p.K437delinsS*HYYLND* | Q6IQ21 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |